uniQure (QURE) Competitors $52.34 -0.57 (-1.08%) As of 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock QURE vs. RDY, ASND, VTRS, ROIV, ELAN, QGEN, BBIO, MRNA, VRNA, and RVMDShould you be buying uniQure stock or one of its competitors? The main competitors of uniQure include Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), QIAGEN (QGEN), BridgeBio Pharma (BBIO), Moderna (MRNA), Verona Pharma PLC American Depositary Share (VRNA), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry. uniQure vs. Its Competitors Dr. Reddy's Laboratories Ascendis Pharma A/S Viatris Roivant Sciences Elanco Animal Health QIAGEN BridgeBio Pharma Moderna Verona Pharma PLC American Depositary Share Revolution Medicines uniQure (NASDAQ:QURE) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership. Is QURE or RDY more profitable? Dr. Reddy's Laboratories has a net margin of 16.99% compared to uniQure's net margin of -1,387.98%. Dr. Reddy's Laboratories' return on equity of 17.25% beat uniQure's return on equity.Company Net Margins Return on Equity Return on Assets uniQure-1,387.98% -1,010.74% -33.27% Dr. Reddy's Laboratories 16.99%17.25%11.63% Which has more volatility and risk, QURE or RDY? uniQure has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.4, meaning that its share price is 60% less volatile than the S&P 500. Do institutionals & insiders hold more shares of QURE or RDY? 78.8% of uniQure shares are owned by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 4.8% of uniQure shares are owned by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has higher earnings & valuation, QURE or RDY? Dr. Reddy's Laboratories has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatiouniQure$27.12M105.90-$239.56M-$3.92-13.35Dr. Reddy's Laboratories$3.81B3.09$663M$0.6621.36 Does the media favor QURE or RDY? In the previous week, uniQure had 1 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 2 mentions for uniQure and 1 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 1.89 beat uniQure's score of 0.25 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the news media. Company Overall Sentiment uniQure Neutral Dr. Reddy's Laboratories Very Positive Do analysts prefer QURE or RDY? uniQure presently has a consensus price target of $71.75, indicating a potential upside of 37.08%. Dr. Reddy's Laboratories has a consensus price target of $16.95, indicating a potential upside of 20.26%. Given uniQure's higher possible upside, analysts clearly believe uniQure is more favorable than Dr. Reddy's Laboratories.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score uniQure 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.83Dr. Reddy's Laboratories 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.83 SummaryDr. Reddy's Laboratories beats uniQure on 8 of the 15 factors compared between the two stocks. Get uniQure News Delivered to You Automatically Sign up to receive the latest news and ratings for QURE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding QURE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QURE vs. The Competition Export to ExcelMetricuniQureMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.85B$3.31B$6.12B$10.53BDividend YieldN/A2.29%5.51%4.67%P/E Ratio-13.2621.5685.7226.88Price / Sales105.90412.90581.25184.02Price / CashN/A46.3226.3031.10Price / Book-373.8610.0213.226.67Net Income-$239.56M-$52.22M$3.30B$276.44M7 Day Performance-10.33%5.57%4.78%3.10%1 Month Performance191.59%11.80%8.42%10.19%1 Year Performance882.01%25.31%87.67%40.32% uniQure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QUREuniQure3.7754 of 5 stars$52.34-1.1%$71.75+37.1%+836.5%$2.85B$27.12M-13.26500Analyst ForecastAnalyst RevisionRDYDr. Reddy's Laboratories3.3031 of 5 stars$14.21+0.3%$16.95+19.3%-9.8%$11.86B$3.81B21.5227,811Positive NewsASNDAscendis Pharma A/S3.1514 of 5 stars$191.99+1.2%$244.36+27.3%+47.8%$11.83B$393.54M-37.211,017Positive NewsVTRSViatris1.2927 of 5 stars$9.52+0.3%$10.40+9.2%-12.6%$11.10B$14.74B-3.2832,000ROIVRoivant Sciences3.4783 of 5 stars$15.17+1.4%$19.94+31.4%+42.9%$10.36B$29.05M-21.67860ELANElanco Animal Health2.6108 of 5 stars$19.63+3.7%$18.33-6.6%+41.1%$9.75B$4.44B22.829,000Analyst UpgradeGap UpQGENQIAGEN4.4703 of 5 stars$43.85-0.2%$49.69+13.3%+10.9%$9.75B$1.98B25.915,765BBIOBridgeBio Pharma4.2205 of 5 stars$50.05+2.1%$63.94+27.8%+116.4%$9.57B$221.90M-12.24400MRNAModerna4.3504 of 5 stars$24.49-0.5%$41.81+70.7%-54.3%$9.53B$3.24B-3.255,800VRNAVerona Pharma PLC American Depositary Share1.9204 of 5 stars$106.69flat$109.00+2.2%+234.0%$9.20B$42.28M-107.7730Positive NewsRVMDRevolution Medicines4.2961 of 5 stars$43.92+3.3%$73.67+67.7%-1.6%$8.21B$11.58M-9.76250 Related Companies and Tools Related Companies RDY Alternatives ASND Alternatives VTRS Alternatives ROIV Alternatives ELAN Alternatives QGEN Alternatives BBIO Alternatives MRNA Alternatives VRNA Alternatives RVMD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QURE) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding uniQure N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share uniQure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
